companies

Methinks

Founded 2016
Employees 15+
Primary contact
Pier01, Office 2D2
Plaça de Pau Vila 1
08039 Barcelona
Catalonia
Spain
+34 600 036 464
Links
https://www.methinks.ai/
Diseases & Conditions
Sections
Technologies
Methinks has developed medical imaging software that detects cerebral artery occlusions and hemorrhages using artificial intelligence without the need for a CT scan with contrast. The company's tech reduces time-to-treatment, enabling radiologists to communicate with hospitals, stroke units, and healthcare professionals. While Methinks is currently focusing on strokes, the second cause of death and a major cause of disability in the world, it also aims to tackle other severe diseases.
Select partners: Barcelona's Vall d'Hebron University Hospital, Cooper University Healthcare.
Founded 2016
Employees 15+
Primary contact
Pier01, Office 2D2
Plaça de Pau Vila 1
08039 Barcelona
Catalonia
Spain
+34 600 036 464
Links
https://www.methinks.ai/
Diseases & Conditions
Sections
Technologies

Funding 💰

Select investors Nina Capital, EIT Health, Capital Cell

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Big market: Methinks's initial focus is on strokes, which affect 17 million people each year globally. Going forward, the plan is also to tackle other severe diseases.
  • Improving access: Advanced stroke assessment is not available 24/7 in more than 50% of hospitals worldwide. Methinks wants to change that.
  • Proven founder: Cristian Martí was a founder and former CEO of Coordina, which was later acquired by TomTom.
  • Great team: Methinks' directors and shareholders include some of the top specialists in the world (Tudor Jovin, Lluís Donoso, Àngel Chamorro and Demetrius Lopes) and entrepreneurs like Marc Ribó (co-founder of Anaconda Biomed) and Marc Subirats (Advance Medical and Nina Capital).

Awards & Recognitions 🏆

  • 2020 Among Sifted's 20 Spanish healthtech companies to watch 🔗

Quotes 💬

“
Methinks is already working for research purposes at Hospital Vall d'Hebron. The results we are seeing are outstanding and make us optimistic about the future of this technology.
— Marc Ribó, Stroke Neurologist and Interventionalist at Hospital Vall d'Hebron in Barcelona
“
As a clinician with the dual perspective of a vascular neurologist and neurointerventionalist I am increasingly convinced that the simplest and fastest imaging modalities used to select acute stroke patients for thrombectomy are the ones most clinically beneficial. Methinks, the first company whose vision is to develop this concept into a clinically established paradigm is backed by unique technology and an outstanding team and has the potential to disrupt acute stroke systems of care.
— Tudor Jovin, Chairman and Chief of Neurology at Cooper University Healthcare, New Jersey
Last update: August 22, 2022